###begin article-title 0
###xml 61 65 <span type="species:ncbi:10090">mice</span>
Collagen-induced arthritis is exacerbated in IL-10-deficient mice
###end article-title 0
###begin p 1
###xml 302 305 302 305 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 328 331 328 331 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 619 622 619 622 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 633 636 633 636 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 716 719 716 719 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 774 777 774 777 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 931 932 927 928 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 940 942 936 938 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2a</sub>
###xml 349 353 <span type="species:ncbi:10090">mice</span>
###xml 564 568 <span type="species:ncbi:10090">mice</span>
###xml 637 641 <span type="species:ncbi:10090">mice</span>
###xml 720 724 <span type="species:ncbi:10090">mice</span>
IL-10 is a potent immunoregulatory cytokine attenuating a wide range of immune effector and inflammatory responses. In the present study, we assess whether endogenous levels of IL-10 function to regulate the incidence and severity of collagen-induced arthritis. DBA/1 wildtype (WT), heterozygous (IL-10+/-) and homozygous (IL-10-/-) IL-10-deficient mice were immunized with type II collagen. Development of arthritis was monitored over time, and collagen-specific cytokine production and anticollagen antibodies were assessed. Arthritis developed progressively in mice immunized with collagen, and 100% of the WT, IL-10+/-, and IL-10-/- mice were arthritic at 35 days. However, the severity of arthritis in the IL-10-/- mice was significantly greater than that in WT or IL-1+/- animals. Disease severity was associated with reduced IFN-gamma levels and a dramatic increase in CD11b-positive macrophages. Paradoxically, both the IgG1 and IgG2a anticollagen antibody responses were also significantly reduced. These data demonstrate that IL-10 is capable of controlling disease severity through a mechanism that involves IFN-gamma. Since IL-10 levels are elevated in rheumatoid arthritis synovial fluid, these findings may have relevance to rheumatoid arthritis.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 113 114 113 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 115 116 115 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 181 182 181 182 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 204 205 204 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 206 207 206 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 563 564 555 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 565 566 557 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 774 775 766 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 776 778 768 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 151 157 <span type="species:ncbi:10090">murine</span>
IL-10 is a potent monocyte/macrophage regulatory cytokine that inhibits expression of proinflammatory mediators [1,2]. Monocytes/macrophages, B cells, murine Th2 cells, and some CD8+ cells produce IL-10 [3,4]. Macrophages rapidly produce proinflammatory cytokines such as tumor necrosis factor alpha (TNF-alpha), IL-1 and IL-12 after activation with lipopolysaccharide or IFN-gamma, while production of IL-10 is delayed. Once IL-10 is produced it functions in an autoregulatory fashion to suppress proinflammatory cytokine mRNA expression and protein production [5-7]. In addition, IL-10 suppresses the expression of MHC class II molecules and costimulatory molecules such as intercellular adhesion molecule 1 and B7, leading to reduction in T-cell macrophage interactions [8-10].
###end p 3
###begin p 4
###xml 139 141 139 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 142 144 142 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 249 251 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 252 254 252 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 359 361 359 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 499 501 499 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 502 504 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 718 720 714 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 877 879 873 875 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 367 375 <span type="species:ncbi:9606">patients</span>
The selective suppression of Th1 cell activity is believed to be due to IL-10 inhibition of IL-12, a differentiation factor for Th1 cells [11,12]. The release of reactive oxygen and nitrogen intermediates by macrophages is also suppressed by IL-10 [13,14]. In addition, IL-10 stimulates the production of cytokine inhibitors such as IL-1 receptor antagonist [15]. In patients with rheumatoid arthritis, IL-10 is produced by synovial membrane cells and is found at high levels in the synovial fluid [16,17]. It has been shown that suppression of IL-10 production by synovial cells is associated with increased levels of IL-1 and TNF-alpha, suggesting that IL-10 plays a suppressive role in rheumatoid arthritis joints [16]. It was also observed that IL-10 directly stimulated proteoglycan synthesis and reversed the cartilage degradation induced by activated mononuclear cells [18]. These immunosuppressive activities indicate that IL-10 is a potential therapeutic approach for autoimmune diseases.
###end p 4
###begin p 5
###xml 222 224 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 225 227 225 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 309 316 309 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 395 397 395 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
In animal models of arthritis, systemic treatment with IL-10 and adenovirus-mediated transfer of viral IL-10 moderately suppresses the development of arthritis, but is significantly more effective when combined with IL-4 [19-24]. The evidence for the importance of IL-10 is further supported by the fact that in vivo anti-IL-10 treatment accelerates disease in collagen-induced arthritis (CIA) [22].
###end p 5
###begin p 6
###xml 406 413 406 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 566 569 566 569 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 586 590 <span type="species:ncbi:10090">mice</span>
Most studies focused on investigating the role of IL-10 in models of arthritis have involved administration of neutralizing antibodies, large amounts of IL-10, or gene therapy in experimental animals. While these studies are helpful in broadly defining the function of IL-10, it is difficult to determine the cytokine dose and timing by these means. To address the effects of complete elimination of IL-10 in vivo on the development of CIA and to understand the mechanism responsible for IL-10 regulation, we examined the development of arthritis in homozygous IL-10-/- IL-10-deficient mice.
###end p 6
###begin title 7
Materials and methods
###end title 7
###begin title 8
Animals, antigens, and immunization procedure
###end title 8
###begin p 9
###xml 9 12 9 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 58 60 58 60 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 173 176 173 176 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 13 17 <span type="species:ncbi:10090">mice</span>
###xml 177 181 <span type="species:ncbi:10090">mice</span>
The IL-10-/- mice were generated as previously described [25]. The original genetic background of these animals was a mixture of the strains 129/Ola and C57BL/6. These IL-10-/- mice were backcrossed to DBA/1 for six generations and further backcrossed for an additional two generations to DBA/1 (Jackson Laboratories, Bar Harbor, MA, USA) in our laboratory.
###end p 9
###begin p 10
###xml 173 176 173 176 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 192 200 192 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 4 8 <span type="species:ncbi:10090">mice</span>
###xml 177 181 <span type="species:ncbi:10090">mice</span>
All mice were typed for the IL-10 mutation by PCR using primer sets that detect either the DBA/1 wildtype (WT) or the mutated IL-10 gene. In addition, splenocytes from IL-10-/- mice activated in vitro did not produce IL-10.
###end p 10
###begin p 11
###xml 9 12 9 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 173 175 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 216 219 216 219 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 229 232 229 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 13 17 <span type="species:ncbi:10090">mice</span>
###xml 87 94 <span type="species:ncbi:9031">Chicken</span>
###xml 233 237 <span type="species:ncbi:10090">mice</span>
###xml 271 278 <span type="species:ncbi:9031">chicken</span>
###xml 338 341 <span type="species:ncbi:31658">CFA</span>
The IL-10-/- mice were maintained in sterilized bedding and food with acidified water. Chicken type II collagen was used for generation of arthritis as described elsewhere [26]. Male and female WT, heterozygous IL-10+/- and IL-10-/- mice were immunized once with 100 mug chicken type II collagen emulsified in complete Freund's adjuvant (CFA) (Difco, Detroit, MI, USA) by intradermal injection at the base of the tail.
###end p 11
###begin title 12
Assessment of arthritis
###end title 12
###begin p 13
###xml 526 528 525 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
Animals were examined for the onset of joint swelling every other day. A standard scoring system based upon redness and swelling of each paw (ranging from 0 to 4 for each paw, thus resulting in a possible maximum severity score of 16) was used for the assessment of disease severity. Histologic studies were performed to determine the extent of joint damage. At the end of the experiment, hind paws were dissected, fixed, and decalcified before being embedded in paraffin, and were sectioned at 6 mum as previously described [27]. Sagittal sections were stained with H & E.
###end p 13
###begin title 14
###xml 50 58 50 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
Assessment of cytokine production by spleen cells in vitro
###end title 14
###begin p 15
###xml 142 144 142 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 168 169 168 169 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 300 306 <span type="species:ncbi:9913">bovine</span>
###xml 644 649 <span type="species:ncbi:10090">mouse</span>
Spleens were obtained at various time points after immunization with collagen. Single cell suspensions were prepared as previously described [28]. Splenocytes (2.0 x 106 cells/ml) were incubated in 24-well Falcon plates (Fisher Scientific, Pittsburgh, PA, USA) in RPMI-1640 media containing 7% fetal bovine serum (Life Technologies, Grand Island, NY, USA), 100 U/ml penicillin, 100 mug/ml streptomycin, 2 mM L-glutamine, 50 mM 2-ME, 1 mM sodium pyruvate, 0.01 mM nonessential amino acids, and 10 mM HEPES. Cells were stimulated in the presence or absence of collagen (100 mug/ml). IFN-gamma was measured from day 5 supernatant using the OptEIA mouse cytokine detection system (BD PharMingen, San Diego, CA, USA).
###end p 15
###begin title 16
Measurement of immunoglobulin isotypes
###end title 16
###begin p 17
###xml 254 255 253 254 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 262 264 261 263 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2a</sub>
###xml 341 342 340 341 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 350 352 349 351 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2a</sub>
###xml 480 481 479 480 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 488 490 487 489 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2a</sub>
###xml 138 145 <span type="species:ncbi:9031">chicken</span>
###xml 233 239 <span type="species:ncbi:9986">rabbit</span>
###xml 245 250 <span type="species:ncbi:10090">mouse</span>
###xml 459 465 <span type="species:ncbi:9986">rabbit</span>
###xml 471 476 <span type="species:ncbi:10090">mouse</span>
An ELISA was used to measure isotype-specific antibodies in serial dilutions (1:500-1.:2500) of sera. ELISA plates were coated with 1 mug chicken type II collagen. Collagen-specific IgG isotypes were detected with peroxidase-labeled rabbit anti-mouse IgG1 or IgG2a (Zymed Laboratories, San Francisco, CA, USA). Titrated concentrations of IgG1 and IgG2a myeloma proteins were used to generate a standard curve, and the IgGs were detected with the same labeled rabbit anti-mouse IgG1 or IgG2a antiserum.
###end p 17
###begin title 18
Flow cytometry
###end title 18
###begin p 19
###xml 225 228 <span type="species:ncbi:10116">rat</span>
Flow cytometry was performed on freshly isolated spleen cells. Immunofluorescence staining of cell surface markers was performed using FITC-labeled antibodies against CD3, B220, CD11b, and CD11c (BD PharMingen). FITC-labeled rat IgG isotypes were used as controls. FcRs were blocked using anti-FcR antibody (24G2). Flow cytometric analysis was performed using a FACS Caliburflow cytometer utilizing CELLQuest software (Becton Dickinson, San Jose, CA, USA).
###end p 19
###begin title 20
Statistical analysis
###end title 20
###begin p 21
###xml 151 152 151 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
Analysis of the arthritis score and disease incidence at different time points were carried out using the nonparametric Mann-Whitney U test. Student's t test was used for statistical analysis of all other data. Analyses were performed using SPSS software (SPSS, Chicago, IL, USA).
###end p 21
###begin title 22
Results
###end title 22
###begin title 23
###xml 23 27 <span type="species:ncbi:10090">mice</span>
Augmented CIA in DBA/1 mice lacking IL-10
###end title 23
###begin p 24
###xml 176 179 176 179 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 190 193 190 193 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 238 241 <span type="species:ncbi:31658">CFA</span>
###xml 287 291 <span type="species:ncbi:10090">mice</span>
To determine whether IL-10 functions as an endogenous inhibitor of inflammatory arthritis, we examined the development of disease using the CIA model. Male and female WT, IL-10+/-, and IL-10-/- littermates were immunized with collagen in CFA intradermally. Data from the male and female mice were pooled because there was no significant difference between the two groups.
###end p 24
###begin p 25
###xml 92 95 92 95 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 132 135 132 135 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 203 206 203 206 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 262 265 262 265 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 398 401 398 401 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 475 478 475 478 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 490 492 490 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 4 8 <span type="species:ncbi:10090">mice</span>
###xml 96 100 <span type="species:ncbi:10090">mice</span>
###xml 136 140 <span type="species:ncbi:10090">mice</span>
###xml 266 270 <span type="species:ncbi:10090">mice</span>
###xml 402 406 <span type="species:ncbi:10090">mice</span>
###xml 479 483 <span type="species:ncbi:10090">mice</span>
All mice succumb to arthritis but the time of onset was somewhat delayed in the WT and IL-10+/- mice compared with that in the IL-10-/- mice (Fig. 1a). Interestingly, the number of arthritic WT and IL-10+/- animals began to recede after day 35, whereas all IL-10-/- mice were still arthritic at the time of termination of the experiments, although with reduced severity. Arthritis severity in IL-10-/- mice was significantly exacerbated in comparison with that of WT or IL-10+/- mice (Fig. 1b).
###end p 25
###begin p 26
###xml 163 165 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 166 168 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
Inflamed joints showed typical histopathological abnormalities described previously (synovial proliferation, leukocyte infiltration, cartilage and bone erosions) [29,30], which correlated well with the severity of the clinical symptoms.
###end p 26
###begin p 27
Taken together, the results described demonstrate that IL-10 is important for controlling disease severity.
###end p 27
###begin title 28
###xml 52 56 <span type="species:ncbi:10090">mice</span>
Anticollagen antibody is reduced in IL-10-deficient mice
###end title 28
###begin p 29
###xml 124 126 124 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 402 405 402 405 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 484 487 484 487 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 499 500 499 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 515 516 515 516 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 528 530 528 530 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2a</sub>
###xml 406 410 <span type="species:ncbi:10090">mice</span>
###xml 488 492 <span type="species:ncbi:10090">mice</span>
Induction of CIA is dependent on B cells, and high doses of antibodies are pathogenic when transferred to naive recipients [31]. IL-10 can affect both the viability and the production of immunoglobulin by B cells [32,33]. To determine whether the augmentation in CIA correlated with an alteration in anticollagen antibodies, we collected sera from animals at the time of sacrifice. Interestingly, IL-10-/- mice produced significantly less anticollagen antibody than either WT or IL-10+/- mice (Fig. 2). Both the IgG1 and the IgG2a isotypes of anticollagen antibodies were substantially reduced.
###end p 29
###begin p 30
These results suggest that a decrease in anticollagen antibody may be the result of a requirement for IL-10 in B-cell antibody production.
###end p 30
###begin title 31
###xml 48 52 <span type="species:ncbi:10090">mice</span>
IFN-gamma levels are reduced in IL-10-deficient mice
###end title 31
###begin p 32
###xml 494 496 470 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 497 499 473 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 61 65 <span type="species:ncbi:10090">mice</span>
###xml 460 464 <span type="species:ncbi:10090">mice</span>
IFN-gamma production is observed early in collagen-immunized mice, and progressively increases with the time of clinical manifestation of arthritis. Although the level of IFN-gamma correlates with disease, IFN-gamma appears to play a dual role in disease activity. Anti-IFN-gamma treatment early in the course of disease suppresses arthritis, whereas neutralization of IFN-gamma late in disease exacerbates arthritis. In addition, IFN-gamma receptor-deficient mice exhibit exacerbated disease [34,35].
###end p 32
###begin p 33
###xml 133 136 129 132 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 147 150 143 146 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 262 263 258 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 325 328 317 320 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 371 374 363 366 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 151 155 <span type="species:ncbi:10090">mice</span>
###xml 198 202 <span type="species:ncbi:10090">mice</span>
###xml 329 333 <span type="species:ncbi:10090">mice</span>
We were therefore interested in determining whether the levels of IFN-gamma correlated with arthritis in collagen-immunized WT, IL-10+/-, and IL-10-/- mice. Splenocytes were isolated from immunized mice and cultured in the presence and absence of collagen (Fig. 3). IFN-gamma levels were significantly suppressed in the IL-10-/- mice in comparison with either WT or IL-10+/- animals.
###end p 33
###begin p 34
These results confirm that reduced levels of IFN-gamma were associated with exacerbated arthritis in collagen-immunized animals. These data also suggest that IL-10 positively regulates IFN-gamma, either directly or indirectly.
###end p 34
###begin title 35
###xml 5 6 5 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
CD11b+ expansion correlates with reduced IL-10
###end title 35
###begin p 36
###xml 8 13 8 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 176 177 172 173 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 185 187 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 201 204 197 200 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 328 329 320 321 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 97 101 <span type="species:ncbi:10090">mice</span>
###xml 137 140 <span type="species:ncbi:31658">CFA</span>
###xml 205 209 <span type="species:ncbi:10090">mice</span>
Matthys et al. recently showed that the enhanced severity of CIA in IFN-gamma receptor-deficient mice immunized with type II collagen in CFA is due to an expansion of the CD11b+ cells [36]. Since IL-10-/- mice produce reduced levels of IFN-gamma, we were interested in determining whether there was a specific expansion of CD11b+ cells.
###end p 36
###begin p 37
###xml 50 53 50 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 69 70 69 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8</sup>
###xml 118 119 116 117 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8</sup>
###xml 174 175 170 171 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 238 239 234 235 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 274 277 270 273 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 304 305 300 301 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 319 320 315 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 421 422 417 418 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 451 454 447 450 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 54 58 <span type="species:ncbi:10090">mice</span>
###xml 103 107 <span type="species:ncbi:10090">mice</span>
###xml 212 216 <span type="species:ncbi:10090">mice</span>
###xml 278 282 <span type="species:ncbi:10090">mice</span>
###xml 455 459 <span type="species:ncbi:10090">mice</span>
Although the spleen cell number increased in IL-10-/- mice (1.42 x 108 +/- 0.17) in comparison with WT mice (0.84 x 108 +/- 0.23), there was a specific expansion of the CD11b+ cell population. The spleen from WT mice contained 10.7% CD11b+ cells, whereas the spleen of IL-10-/- mice contained 22.5% CD11b+ cells (Table 1). When the percentage of cells was corrected for cell number, there was a 3.7-fold increase in CD11b+ cells in the spleen of IL-10-/- mice. The net number of T cells, B cells, and dendritic cells was not significantly different.
###end p 37
###begin p 38
###xml 88 89 84 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 219 220 211 212 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
These data are consistent with the inhibitory effects of IFN-gamma on expansion of CD11b+ cells. The data suggest that IL-10 is important for controlling IFN-gamma and/or other cytokines involved in the process of CD11b+ cell expansion.
###end p 38
###begin p 39
###xml 80 81 80 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 102 105 102 105 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 268 271 264 267 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 359 362 352 355 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 377 378 370 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 106 110 <span type="species:ncbi:10090">mice</span>
###xml 272 276 <span type="species:ncbi:10090">mice</span>
###xml 299 303 <span type="species:ncbi:10090">mice</span>
In an attempt to understand the mechanism responsible for the expansion of CD11b+ macrophages in IL-10-/- mice, we examined cytokines associated with inflammation and Th1 cell phenotype. We were unable to detect any difference in the IL-12 or TNF-alpha levels in IL-10-/- mice in comparison with WT mice. However, IL-1beta was significantly increased in IL-10-/- animals (Fig. 4).
###end p 39
###begin p 40
###xml 76 77 73 74 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
These results suggest the possibility that IL-1beta may play a role in CD11b+ cell expansion.
###end p 40
###begin title 41
Discussion
###end title 41
###begin p 42
###xml 307 309 307 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 310 312 310 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 313 315 313 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 316 318 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 450 452 450 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 453 455 453 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 587 594 587 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 595 597 595 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 708 711 704 707 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 712 716 <span type="species:ncbi:10090">mice</span>
IL-10 appears to play an important role in the regulation of several autoimmune disease models. Treatment with recombinant IL-10 in CIA, in proteoglycan-induced arthritis, and in experimental autoimmune encephalomyelitis reduced disease severity, and neutralizing IL-10 with antibodies exacerbated disease [19,20,22,23]. The present data are consistent with previous results and show that a complete absence of IL-10 exacerbates inflammation in CIA [37-39]. The anti-inflammatory properties of IL-10 suggest that endogenous IL-10 may function as a regulator of proinflammatory mediators in vivo[39]. It is interesting, however, that disease severity inversely correlates with the levels of IFN-gamma in IL-10-/- mice, suggesting that IL-10 may control disease activity via regulating IFN-gamma responses.
###end p 42
###begin p 43
###xml 242 244 230 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 420 422 400 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 615 617 587 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 618 620 590 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 499 503 <span type="species:ncbi:10090">mice</span>
###xml 546 550 <span type="species:ncbi:10090">mice</span>
###xml 730 734 <span type="species:ncbi:10090">mice</span>
Although CIA is considered a Th1-type disease mediated by IFN-gamma, the role of IFN-gamma in the pathogenesis of CIA is not clearly understood. IFN-gamma appears to have two separate functions, disease promoting as well as disease limiting [40]. Neutralization of IFN-gamma with antibodies early in the course of disease exerts a suppressive effect, whereas anti-IFN-gamma treatment late in disease enhances arthritis [41]. Also, disease severity in CIA is enhanced in IFN-gamma receptor-deficient mice, and loss of the IFN-gamma receptor turns mice normally resistant to CIA into an arthritis-susceptible strain [34,35]. IFN-gamma thus provides a dominant protective effect in CIA. The reduction in IFN-gamma in IL-10-deficient mice is consistent with the disease-limiting properties of IFN-gamma. These results suggest that IL-10 plays an unexpected role in regulating IFN-gamma production in CIA.
###end p 43
###begin p 44
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 160 162 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 398 399 386 387 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 468 469 456 457 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 501 504 489 492 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 578 585 562 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 634 637 614 617 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 676 677 656 657 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 763 766 740 743 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 809 810 786 787 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 872 874 846 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 175 179 <span type="species:ncbi:10090">mice</span>
###xml 211 214 <span type="species:ncbi:31658">CFA</span>
###xml 288 292 <span type="species:ncbi:10090">mice</span>
###xml 325 329 <span type="species:ncbi:10090">mice</span>
###xml 505 509 <span type="species:ncbi:10090">mice</span>
###xml 638 642 <span type="species:ncbi:10090">mice</span>
###xml 767 771 <span type="species:ncbi:10090">mice</span>
Recent work by Matthys et al. demonstrates that the protective effect of IFN-gamma is dependent on the presence of the mycobacterial component of the adjuvant [36]. Only when mice are immunized with collagen in CFA is there an increase in disease severity in IFN-gamma receptor-deficient mice. Ablation of IFN-gamma in these mice is associated with extramedullary hemopoiesis and expansion of CD11b+ cells. Consistent with this observation, a similar increase in CD11b+ cells was observed in the IL-10-/- mice. These data suggest that IL-10 controls the IFN-gamma concentration in vivo and that the reduced level of IFN-gamma in IL-10-/- mice contributes to expansion of CD11b+ cells and increase in disease severity. The increase in IL-1beta we observed in IL-10-/- mice may account for the increase in CD11b+ cells as IL-1beta is known for its hematopoietic properties [42].
###end p 44
###begin p 45
###xml 195 198 195 198 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 438 446 430 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 451 458 443 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 481 483 473 475 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2a</sub>
###xml 495 497 487 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 586 588 574 576 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2a</sub>
###xml 632 633 620 621 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 199 203 <span type="species:ncbi:10090">mice</span>
In addition to the cellular immune response, anticollagen antibodies are required for the development of arthritis. In the studies presented, despite the increase in disease severity in the IL-10-/- mice, anticollagen antibodies are reduced. This reduction in antibody levels may be a direct effect on B cells due to a loss of IL-10 or may be an indirect effect due to downregulation by IFN-gamma. The Th1 cytokine IFN-gamma is important in vitro and in vivo for enhancement of IgG2a secretion [43]. It is expected that loss of IFN-gamma should result in a reduced collagen-specific IgG2a response, but it is unexpected that the IgG1 response would also be reduced. These results indicate that IL-10 has a direct effect on maintaining antibody production in CIA. In addition, loss of the anti-inflammatory effect of IL-10 appears to overdrive the requirements for high levels of anticollagen antibodies in CIA.
###end p 45
###begin title 46
Conclusion
###end title 46
###begin p 47
###xml 87 94 87 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
In summary, these results suggest that IL-10 is an important regulator of inflammation in vivo. In CIA, a deficiency in IL-10 leads to an increase in disease severity. The corresponding reduction in IFN-gamma levels and the expansion of CD11b+ cells suggests a potential mechanism for IL-10 regulation of CIA.
###end p 47
###begin title 48
Abbreviations
###end title 48
###begin p 49
###xml 0 3 <span type="species:ncbi:31658">CFA</span>
CFA = complete Freund's adjuvant; CIA = collagen-induced arthritis; ELISA = enzyme-linked immunosorbent assay; FACS = fluorescence-activated cell sorting; FITC = fluorescein isothiocyanate; H & E = hematoxylin and eosin; IFN = interferon; IL = interleukin; MHC = major histocompatibility complex; PCR = polymerase chain reaction; Th cells = T helper cells; TNF-alpha = tumor necrosis factor alpha; WT = DBA/1 wildtype.
###end p 49
###begin title 50
Acknowledgement
###end title 50
###begin p 51
The present work was supported by the National Institutes of Health grants AR45652 (AF, TG, and JZ), AR47412 (JZ), and AR47657 (AF).
###end p 51
###begin article-title 52
Interleukin-10.
###end article-title 52
###begin article-title 53
Properties and functions of interleukin-10.
###end article-title 53
###begin article-title 54
IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells.
###end article-title 54
###begin article-title 55
###xml 27 32 <span type="species:ncbi:10090">mouse</span>
Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin 10.
###end article-title 55
###begin article-title 56
###xml 54 59 <span type="species:ncbi:9606">human</span>
Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes.
###end article-title 56
###begin article-title 57
IL-10 inhibits cytokine production by activated macrophages.
###end article-title 57
###begin article-title 58
###xml 72 77 <span type="species:ncbi:9606">human</span>
Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression.
###end article-title 58
###begin article-title 59
###xml 79 84 <span type="species:ncbi:9606">human</span>
Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes.
###end article-title 59
###begin article-title 60
###xml 105 110 <span type="species:ncbi:9606">human</span>
Interleukin-10 inhibits interferon-gamma-induced intercellular adhesion molecule-1 gene transcription in human monocytes.
###end article-title 60
###begin article-title 61
IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression.
###end article-title 61
###begin article-title 62
###xml 32 37 <span type="species:ncbi:9606">human</span>
Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells.
###end article-title 62
###begin article-title 63
Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells.
###end article-title 63
###begin article-title 64
Macrophage deactivation by interleukin 10.
###end article-title 64
###begin article-title 65
IL-10 inhibits parasite killing and nitrogen oxide production by IFN-gamma-activated macrophages.
###end article-title 65
###begin article-title 66
###xml 106 111 <span type="species:ncbi:9606">human</span>
Interleukin 10 (IL-10) upregulates IL-1 receptor antagonist production from lipopolysaccharide-stimulated human polymorphonuclear leukocytes by delaying mRNA degradation.
###end article-title 66
###begin article-title 67
Immunoregulatory role of interleukin 10 in rheumatoid arthritis.
###end article-title 67
###begin article-title 68
###xml 34 42 <span type="species:ncbi:9606">patients</span>
Elevated interleukin-10 levels in patients with rheumatoid arthritis.
###end article-title 68
###begin article-title 69
Prevention and reversal of cartilage degradation in rheumatoid arthritis by interleukin-10 and interleukin-4.
###end article-title 69
###begin article-title 70
Interleukin-10 inhibition of the progression of established collagen-induced arthritis.
###end article-title 70
###begin article-title 71
###xml 49 53 <span type="species:ncbi:10090">mice</span>
Effect of IL-10 on collagen-induced arthritis in mice.
###end article-title 71
###begin article-title 72
###xml 119 123 <span type="species:ncbi:10116">rats</span>
Interleukin-10 suppresses the development of collagen type II-induced arthritis and ameliorates sustained arthritis in rats.
###end article-title 72
###begin article-title 73
###xml 44 50 <span type="species:ncbi:10090">murine</span>
Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction.
###end article-title 73
###begin article-title 74
###xml 44 48 <span type="species:ncbi:10090">mice</span>
Inhibition of collagen-induced arthritis in mice by viral IL-10 gene transfer.
###end article-title 74
###begin article-title 75
###xml 58 64 <span type="species:ncbi:10090">murine</span>
Adenovirus-mediated transfer of viral IL-10 gene inhibits murine collagen-induced arthritis.
###end article-title 75
###begin article-title 76
###xml 25 29 <span type="species:ncbi:10090">mice</span>
Interleukin-10-deficient mice develop chronic enterocolitis [see comments].
###end article-title 76
###begin article-title 77
###xml 75 79 <span type="species:ncbi:10090">mice</span>
Increased resistance to collagen-induced arthritis in CD44-deficient DBA/1 mice.
###end article-title 77
###begin article-title 78
###xml 41 45 <span type="species:ncbi:10090">mice</span>
Proteoglycan-induced arthritis in BALB/c mice. Clinical features and histopathology.
###end article-title 78
###begin article-title 79
Activation of B cells by autoreactive T cells: cloned autoreactive T cells activate B cells by two distinct pathways.
###end article-title 79
###begin article-title 80
###xml 105 109 <span type="species:ncbi:10090">mice</span>
Proteoglycan-induced polyarthritis and spondylitis adoptively transferred to naive (nonimmunized) BALB/c mice.
###end article-title 80
###begin article-title 81
###xml 52 56 <span type="species:ncbi:10090">mice</span>
Proteoglycan (Aggrecan)-induced arthritis in BALB/c mice is a Th1-type disease regulated by Th2 cytokines.
###end article-title 81
###begin article-title 82
###xml 48 52 <span type="species:ncbi:10090">mice</span>
Serum transfer of collagen-induced arthritis in mice.
###end article-title 82
###begin article-title 83
Interleukin 10, a novel B cell stimulatory factor: unresponsiveness of X chromosome-linked immunodeficiency B cells.
###end article-title 83
###begin article-title 84
Lymphokine control of type 2 antigen response. IL-10 inhibits IL-5- but not IL-2-induced Ig secretion by T cell-independent antigens.
###end article-title 84
###begin article-title 85
###xml 71 75 <span type="species:ncbi:10090">mice</span>
Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice.
###end article-title 85
###begin article-title 86
###xml 53 57 <span type="species:ncbi:10090">mice</span>
High susceptibility to collagen-induced arthritis in mice lacking IFN-gamma receptors.
###end article-title 86
###begin article-title 87
###xml 154 155 154 155 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 62 66 <span type="species:ncbi:10090">mice</span>
Enhanced autoimmune arthritis in IFN-gamma receptor-deficient mice is conditioned by mycobacteria in Freund's adjuvant and by increased expansion of Mac-1+ myeloid cells.
###end article-title 87
###begin article-title 88
###xml 22 26 <span type="species:ncbi:10090">mice</span>
IL-10-deficient B10.Q mice develop more severe collagen-induced arthritis, but are protected from arthritis induced with anti-type II collagen antibodies.
###end article-title 88
###begin article-title 89
Susceptibility to collagen-induced arthritis: cytokine-mediated regulation.
###end article-title 89
###begin article-title 90
###xml 64 70 <span type="species:ncbi:10090">murine</span>
Absence of endogeneous interleukin-10 enhances the evolution of murine type-II collagen-induced arthritis.
###end article-title 90
###begin article-title 91
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE).
###end article-title 91
###begin article-title 92
###xml 39 45 <span type="species:ncbi:10090">murine</span>
Biphasic effect of interferon-gamma in murine collagen-induced arthritis.
###end article-title 92
###begin article-title 93
IL-1beta mediates diethyldithiocarbamate-induced granulocyte colony-stimulating factor production and hematopoiesis.
###end article-title 93
###begin article-title 94
Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production.
###end article-title 94
###begin title 95
Figures and Tables
###end title 95
###begin p 96
###xml 88 91 88 91 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 102 105 102 105 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 112 115 112 115 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a)</bold>
###xml 194 195 194 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 212 215 212 215 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 217 218 217 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 239 242 239 242 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 243 244 243 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 264 267 264 267 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b)</bold>
###xml 531 532 529 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 106 110 <span type="species:ncbi:10090">mice</span>
###xml 251 255 <span type="species:ncbi:10090">mice</span>
###xml 562 566 <span type="species:ncbi:10090">mice</span>
Incidence and severity of collagen-induced arthritis (CIA) in DBA/1 wildtype (WT), IL-10+/-, and IL-10-/- mice. (a) Incidence of CIA, expressed as the percentage of arthritic animals in the WT (n = 17), the IL-10+/- (n = 12), and the IL-10-/-(n = 11) mice groups. (b) Disease severity, expressed as the cumulative arthritis score, in affected animals. Values are presented as the mean +/- standard error of the mean, and represent one of two experiments. Severity of arthritis was significantly different between days 20 and 50. * P < 0.05 in comparison with WT mice.
###end p 96
###begin p 97
###xml 55 58 55 58 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 86 87 86 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 100 103 100 103 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 105 106 105 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 122 125 122 125 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 127 128 127 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 305 306 303 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 59 63 <span type="species:ncbi:10090">mice</span>
###xml 135 139 <span type="species:ncbi:10090">mice</span>
###xml 336 340 <span type="species:ncbi:10090">mice</span>
Collagen-specific antibody response is reduced in IL-10-/- mice. DBA/1 wildtype (WT) (n = 17), IL-10+/- (n = 12) and IL-10-/- (n = 11) mice were immunized with collagen, and the serum antibody isotypes to collagen were measured by ELISA. Values are presented as the mean +/- standard error of the mean. * P < 0.05 in comparison with WT mice.
###end p 97
###begin p 98
###xml 37 40 33 36 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 130 137 126 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ex vivo</italic>
###xml 266 269 260 263 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a)</bold>
###xml 291 292 285 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 305 308 299 302 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 310 311 304 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 328 331 322 325 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 333 334 327 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 351 354 345 348 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b)</bold>
###xml 359 360 353 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 376 379 370 373 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 381 382 375 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 396 397 390 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 41 45 <span type="species:ncbi:10090">mice</span>
###xml 94 98 <span type="species:ncbi:10090">mice</span>
###xml 341 345 <span type="species:ncbi:10090">mice</span>
###xml 388 392 <span type="species:ncbi:10090">mice</span>
###xml 427 431 <span type="species:ncbi:10090">mice</span>
IFN-gamma levels are reduced in IL-10-/- mice. Spleens were harvested from collagen-immunized mice and restimulated with collagen ex vivo. Supernatants were harvested on day 5 and assayed by ELISA. Values are presented as the mean +/- standard error of the mean of: (a) DBA/1 wildtype (WT) (n = 17), IL-10+/- (n = 12), and IL-10-/- (n = 11) mice; and (b) WT (n = 13) and IL-10-/- (n = 7) mice. * P < 0.05 in comparison with WT mice.
###end p 98
###begin p 99
###xml 38 41 35 38 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 195 196 190 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 212 215 207 210 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 217 218 212 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 270 271 265 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 42 46 <span type="species:ncbi:10090">mice</span>
###xml 224 228 <span type="species:ncbi:10090">mice</span>
###xml 301 305 <span type="species:ncbi:10090">mice</span>
IL-1beta levels are increased in IL-10-/- mice. Supernatants were harvested on day 5 and assayed by ELISA. Values are presented as the mean +/- standard error of the mean of DBA/1 wildtype (WT) (n = 12) and IL-10-/- (n = 7) mice, and represent one of two experiments. * P < 0.05 in comparison with WT mice. TNF-alpha, tumor necrosis factor alpha.
###end p 99
###begin p 100
###xml 65 68 65 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 99 100 99 100 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
Ratio of cell populations between DBA/1 wildtype spleen and IL-10-/- spleen in IL-10 deficient micea
###end p 100
###begin p 101
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 327 330 325 328 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 411 412 409 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 274 278 <span type="species:ncbi:10090">mice</span>
a The percentage of CD3, B220, CD11c, and CD11b cells was determined by flow cytometry as described in Materials and methods, and the exact number of cells calculated based on the total number of splenocytes. Values are presented as the mean +/- standard deviation of three mice. The ratio was calculated as the number of IL-10-/- cells divided by the number of DBA/1 wildtype cells. * Significantly different (P < 0.05 in comparison with DBA/1 wildtype).
###end p 101

